Sinopharm Group

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Sinopharm Group
public
Traded as SEHK01099 (H share)
Industry Pharmaceutical
Founded
  • 1998 (predecessor)
  • 2003
Founder China National Pharmaceutical Group
Headquarters Sinopharm Plaza, Shanghai, China
Area served
China
Key people
  • Wei Yulin (Chairman)
  • Chen Qiyu (Vice-Chairman)
  • Li Zhiming (President)
Revenue Increase CN¥227.069 billion (2015)
Increase CN¥9.169 billion (2015)
Increase CN¥3.761 billion (2015)
Total assets Increase CN¥138.267 billion (2015)
Total equity Increase CN¥30.052 billion (2015)
Owner Sinopharm Industrial Investment (56.79%)
Parent Sinopharm Industrial Investment
Subsidiaries Sinopharm CNMC
Website www.sinopharmgroup.com.cn
Footnotes / references
in a consolidated basis; equity and profit excluded minority interests; in Hong Kong Financial Reporting Standards[1]
Sinopharm Group Co., Ltd.
Simplified Chinese 国药控股股份有限公司
Traditional Chinese 國藥控股股份有限公司
Literal meaning Sinopharm Holding Joint-Stock Limited Company
Sinopharm Group
Simplified Chinese 国药控股
Traditional Chinese 國藥控股
Literal meaning Sinopharm Holding
Second alternative Chinese name
Simplified Chinese 国控股份有限公司
Traditional Chinese 國控股份有限公司

Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.

Sinopharm Group researches and develops, manufactures, distributes, and markets medicine and other healthcare products[2]. Sinopharm Group manages factories, research laboratories, traditional Chinese medicine plantations, and marketing and distribution networks that extend throughout China.

Its H shares were listed on the Hong Kong Stock Exchange in 2009,[3] with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted.

Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list.[4]

See also[edit]

References[edit]

  1. ^ "2015 Annual Report" (PDF). Sinopharm Group. Hong Kong Stock Exchange. 25 April 2016. Retrieved 22 November 2016. 
  2. ^ "Sinopharm Group Co. Ltd.: Private Company Information - Bloomberg". www.bloomberg.com. Retrieved 2017-07-27. 
  3. ^ China's Sinopharm gets OK for $1 bln HK IPO
  4. ^ https://www.forbes.com/companies/sinopharm-group/

External links[edit]